Inhibitors of RAF inhibit the MAPK pathway that plays an important role in the development and progression of those melanoma carrying the V600E BRAF mutation, but there's a subset of such patients who do not respond to the therapy. Various mechanisms of drug resistance have been proposed which include the clonal heterogeneity of the tumor. We have studied a population of nodular melanoma to investigate the intratumor and intertumor heterogeneity by Laser Capture Microdissection (LCM) analysis. Our results showed that BRAF and NRAS mutations were detected in 47% and 33% of nodular melanoma, respectively, and that there is a discrepancy in mutational pattern of tumoral sample because in the 36% of patients a different mutation, in at least 1 area of the tumor, was found by LCM analysis, giving evidence of the presence of different clonal cells populations. Moreover, we found that mutations in BRAF and NRAS are not mutually exclusive because they were simultaneously present in the same tumor specimens and we observed that when the 2 different mutations were present one is a high-frequency mutation and the other is a low-frequency mutation. This was more evident in lymphonodal metastasis that resulted from wild type to mutational analysis, but showed different mutations following LCM analysis. Therefore, we believed that, when primary tumoral sample results negative to mutational analysis, if it is possible, metastases should be investigated to verify the presence of mutations. Generally, it should be searched for other mutations, in addition to BRAF V600E, so as to better understand the mechanism of drug resistance.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/3.0.

BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma / Chiappetta, Caterina; Proietti, Ilaria; Valentina, Soccodato; Chiara, Puggioni; Roberto, Zaralli; Pacini, Luca; Porta, Natale; Skroza, Nevena; Petrozza, Vincenzo; Potenza, Concetta; DELLA ROCCA, Carlo; DI CRISTOFANO, Claudio. - In: APPLIED IMMUNOHISTOCHEMISTRY AND MOLECULAR MORPHOLOGY. - ISSN 1541-2016. - STAMPA. - 23:3(2015), pp. 172-177. [10.1097/pai.0000000000000071]

BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma

CHIAPPETTA, CATERINA
;
PROIETTI, ILARIA;PACINI, LUCA;PORTA, NATALE;SKROZA, Nevena;PETROZZA, Vincenzo;POTENZA, Concetta;DELLA ROCCA, Carlo;DI CRISTOFANO, CLAUDIO
2015

Abstract

Inhibitors of RAF inhibit the MAPK pathway that plays an important role in the development and progression of those melanoma carrying the V600E BRAF mutation, but there's a subset of such patients who do not respond to the therapy. Various mechanisms of drug resistance have been proposed which include the clonal heterogeneity of the tumor. We have studied a population of nodular melanoma to investigate the intratumor and intertumor heterogeneity by Laser Capture Microdissection (LCM) analysis. Our results showed that BRAF and NRAS mutations were detected in 47% and 33% of nodular melanoma, respectively, and that there is a discrepancy in mutational pattern of tumoral sample because in the 36% of patients a different mutation, in at least 1 area of the tumor, was found by LCM analysis, giving evidence of the presence of different clonal cells populations. Moreover, we found that mutations in BRAF and NRAS are not mutually exclusive because they were simultaneously present in the same tumor specimens and we observed that when the 2 different mutations were present one is a high-frequency mutation and the other is a low-frequency mutation. This was more evident in lymphonodal metastasis that resulted from wild type to mutational analysis, but showed different mutations following LCM analysis. Therefore, we believed that, when primary tumoral sample results negative to mutational analysis, if it is possible, metastases should be investigated to verify the presence of mutations. Generally, it should be searched for other mutations, in addition to BRAF V600E, so as to better understand the mechanism of drug resistance.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/3.0.
braf; melanoma
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma / Chiappetta, Caterina; Proietti, Ilaria; Valentina, Soccodato; Chiara, Puggioni; Roberto, Zaralli; Pacini, Luca; Porta, Natale; Skroza, Nevena; Petrozza, Vincenzo; Potenza, Concetta; DELLA ROCCA, Carlo; DI CRISTOFANO, Claudio. - In: APPLIED IMMUNOHISTOCHEMISTRY AND MOLECULAR MORPHOLOGY. - ISSN 1541-2016. - STAMPA. - 23:3(2015), pp. 172-177. [10.1097/pai.0000000000000071]
File allegati a questo prodotto
File Dimensione Formato  
Chiappetta_BRAF_2015.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 713.9 kB
Formato Adobe PDF
713.9 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/555918
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 35
social impact